´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷ : 2021-11-04±³À°ÀÏÀÚ : 2021-11-04
±³À°Àå¼Ò : ¿Â¶óÀÎ LIVE
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 1ÀÏÂ÷ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°¨¿°ÇÐȸ
¿¬¶ôó : 02-2055-1441
À̸ÞÀÏ :
ksinfect@ksid.or.kr ±³À°Á¾·ù : ³»°ú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°úÀÇ»çÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í Á¤È¸¿ø Àü¹®ÀÇ 100,000 Àü°øÀÇ 60,000 Çлý 40,000ºñȸ¿ø Àü¹®ÀÇ 120,000 Àü°øÀÇ 80,000 Çлý 50,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:00~08:25 How to treat : MDR/XDR TB ÇãÀº¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:25~08:50 How to answer : Consultations from hematologic malignancy unit À̵¿°Ç(°¡Å縯ÀÇ´ë)
±âŸ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 08:50~09:00 Opening remarks ¹é°æ¶õ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:00~09:20 Invasive fungal infection in severe COVID-19 patients °Ã¶ÀÎ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:20~09:40 Ongoing battle against gram-postive bacteria Á¤¿ëÇÊ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 09:40~10:00 Current Perspectives of COVID-19-Associated Pulmonary Aspergillosis in Korea: Multi-centered Retrospective Cohort Study Using Clinical Data Warehouse ÀÌ·¡¼®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:00~10:20 Ç÷¾×Åõ¼® ȯÀÚµé°ú °Ç°ÀÎÀÇ Äڷγª19 ¹é½Å Á¢Á¾¿¡ µû¸¥ ¹æ¾î Ç×ü »ý¼º Â÷ÀÌ ºÐ¼®: a preliminary report ±èºÀ¿µ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:20~10:40 Rifamycins Resistance, rpoB gene mutation, and Clinical Outcome of Staphylococcus Species Isolated from Prosthetic Joint Infection in Korea ±è¼ö¼º(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 10:40~11:00 Persistent serotype 3 and 19A invasive pneumococcal diseases despite high pneumococcal vaccine uptake: serotype-dependent differences in antimicrobial resistance and genetic diversity À±Áø±¸(°í·ÁÀÇ´ë)
ÈÞ½Ä 11-04 ·Ôµ¥È£ÅÚ¿ùµå 11:00~11:10 Break ()
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 11:10~12:00 Therapeutic Potential of Bacteriophage and Endolysin À¯»ó¿(¼¿ï´ë)
ÈÞ½Ä 11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:00~12:10 Break ()
±âŸ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:10~12:40 KSID General Assembly ¹é°æ¶õ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 12:40~13:30 ±¹³» »óȲ¿¡ ÀûÇÕÇÑ Ç×»ýÁ¦ °ü¸® À±¿µ°æ(°í·ÁÀÇ´ë)
ÈÞ½Ä 11-04 ·Ôµ¥È£ÅÚ¿ùµå 13:30~13:40 Break ()
±³À°½Ã°£ 11-04 13:40~13:50 Risk Factors and Microbiological Features of Recurrent Escherichia coli Bloodstream infection ±è¿ëÂù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 13:50~14:00 Risk factor-based analysis of healthcare-associated pneumonia: microbiological distribution, antibiotic resistance and clinical outcomes ÇöÇÐÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:00~14:10 Clinical presentation and impact of carbapenem-resistant Enterobacteriaceae acquisition in patients with hematologic malignancies À̱âÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:10~14:20 Active surveillance of Clostridioides difficile infections in 10 tertiary hospitals ±èÁöÀº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:20~14:30 Serum Irisin levels are decreased in septic patients, and irisin suppresses pro-inflammatory cytokines in mice ÀüÁöÈÆ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:30~14:40 Gut microbiome in chronic HBV infection is associated with a reduced triglyceride level: An experimental mouse model ±èº¸¹Ì(°ºÏ»ï¼ºº´¿ø)
ÈÞ½Ä 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:40~14:50 Break ()
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 14:50~15:00 Predictive laboratory parameters of dynamic changes in viral load in patients with severe fever with thrombocytopenia syndrome ±è¹Ì¼±(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:00~15:10 Safety and immunogenicity of recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike/nucleocapsid proteins: two open-label, phase 1 trials in healthy adults ¾ÈÁø¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:10~15:20 Whole genome sequence analysis were useful evidence for transmission route for COVID-19 virus via Cargo ship from Russia to South Korea À̽ÂÈÆ(Áúº´°ü¸®Ã»)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:20~15:30 Dynamics of COVID-19 infections estimated by Public community mobility in South Korea À¯´ë¼º(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:30~15:40 Viral RNA kinetics of SARS-CoV-2 in non-hospitalized patients according to symptom duration ±èº¸¹Ì(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:40~15:50 The interaction between gut microbiome and humoral immunogenicity after COVID-19 vaccination ¼ºÇý(°í·ÁÀÇ´ë)
ÈÞ½Ä 11-04 ·Ôµ¥È£ÅÚ¿ùµå 15:50~16:00 Break ()
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 16:00~16:30 Experiences of and lessons learned from past pandemics ±è¿ìÁÖ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 16:30~17:00 Problems and lessons in management of COVID-19 Á¤ÀçÈÆ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 11-04 ·Ôµ¥È£ÅÚ¿ùµå 17:00~17:30 Changes and Tasks in national infectious diseases response strategy in post COVID-19 pandemic ÀåÈñâ(±¹¸³º¸°Ç¿¬±¸¿ø)